SCHEMBL5604757

SCHEMBL5604757

O=C(OC(F)(F)C(F)(F)C(F)(F)F)C(F)(F)C(F)(F)F

nearest known ligand 0.37

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11205486 0.82 THRB (0.33) THRB
SCHEMBL5915218 0.81 THRB (0.50) THRB
SCHEMBL15256858 0.80 ALDH1A1 (0.31)
SCHEMBL19470197 0.80 THRB (0.37) THRB
SCHEMBL16547496 0.78 THRB (0.31) THRB
SCHEMBL20571198 0.76 THRB (0.31) THRB
SCHEMBL7986043 0.76 THRB (0.36) THRB
SCHEMBL31253461 0.74 THRB (0.40) THRB
SCHEMBL31253489 0.74 THRB (0.35) THRB
SCHEMBL1766415 0.74 THRB (0.35) THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114621541-A High-temperature-resistant oil-resistant fluorine-containing elastomer composition 江苏千富之丰科技有限公司 2022-06-14 CN disclosed
US-9051259-B2 Process for producing perfluorinated organic compounds SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) 2015-06-09 US disclosed
US-20130245289-A1 Process for producing perfluorinated organic compounds SOLVAY SPECIALTY POLYMERS ITALY S.P.A. (IT) 2013-09-19 US disclosed
EP-1164122-B1 PROCESS FOR PRODUCING FLUORINE COMPOUND THROUGH LIQUID-PHASE FLUORINATION ASAHI GLASS CO LTD (JP) 2007-07-18 EP disclosed
US-7083705-B2 Process for producing a fluorine-containing compound by liquid phase fluorination ASAHI GLASS COMPANY, LIMITED (JP) 2006-08-01 US disclosed
US-6951957-B2 Process for producing a fluorine-containing compound by liquid phase fluorination ASAHI GLASS COMPANY, LIMITED (JP) 2005-10-04 US disclosed
US-20050020855-A1 Process for producing a fluorine-containing compound by liquid phase fluorination ASAHI GLASS COMPANY, LIMITED (JP) 2005-01-27 US disclosed
US-20030204099-A1 Process for producing a fluorine-containing compound by liquid phase fluorination ASAHI GLASS COMPANY, LIMITED (JP) 2003-10-30 US disclosed
US-6586626-B2 Fluorinating compound in liquid phase ASAHI GLASS COMPANY, LIMITED (JP) 2003-07-01 US disclosed
EP-1164122-A9 PROCESS FOR PRODUCING FLUORINE COMPOUND THROUGH LIQUID-PHASE FLUORINATION ASAHI GLASS COMPANY LTD. (JP) 2002-05-15 EP disclosed
US-20020022752-A1 Process for producing a fluorine containing compound by liquid phase fluorination ASAHI GLASS COMPANY, LIMITED (JP) 2002-02-21 US disclosed
EP-1164122-A1 PROCESS FOR PRODUCING FLUORINE COMPOUND THROUGH LIQUID-PHASE FLUORINATION ASAHI GLASS COMPANY LTD. (JP) 2001-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020855-A1 Process for producing a fluorine-containing compound by liquid phase fluorination CFH, HRH3, ERH THRB 3128/4885
US-20130245289-A1 Process for producing perfluorinated organic compounds PFAS, ADH1A, CYP2F1 THRB 737/4885
US-20030204099-A1 Process for producing a fluorine-containing compound by liquid phase fluorination AFF4, AFF2, AFF1 THRB 1933/4885
US-20020022752-A1 Process for producing a fluorine containing compound by liquid phase fluorination AFF2, AFF4, AFF1 THRB 1714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.